Profile data is unavailable for this security.
About the company
CanSino Biologics Inc is a clinical-stage vaccine company in China. The Company's products include Ad5-EBOV vaccine used for Ebola virus, MCV2 and MCV4 vaccines for meningococcus, PBPV vaccine used for pneumococcal and the recombinant novel coronavirus vaccine. Its products are mainly used in meningitis, diphtheria pertussis tetanus (DPT) and pneumonia.
- Revenue in CNY (TTM)370.81m
- Net income in CNY-1.51bn
- Incorporated2009
- Employees1.49k
- LocationCanSino Biologics IncWest District Biomedical Park, No. 185South Avenue, West District, EconomicTIANJIN 300457ChinaCHN
- Phone+86 2 258213766
- Fax+86 2 258213626
- Websitehttp://www.cansinotech.com/
More ▼
7.09%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Rongtong Fund Management Co., Ltd.as of 31 Dec 2023 | 838.40k | 1.26% |
| Yinhua Fund Management Co., Ltd.as of 31 Dec 2023 | 783.46k | 1.17% |
| GF Fund Management Co., Ltd.as of 31 Dec 2023 | 709.82k | 1.06% |
| Penghua Fund Management Co., Ltd.as of 31 Dec 2023 | 582.09k | 0.87% |
| Bosera Asset Management Co., Ltd.as of 31 Dec 2023 | 573.11k | 0.86% |
| Lion Fund Management Co., Ltd.as of 31 Dec 2023 | 480.00k | 0.72% |
| The Vanguard Group, Inc.as of 04 Jul 2024 | 299.74k | 0.45% |
| China Southern Asset Management Co., Ltd.as of 31 Dec 2023 | 218.03k | 0.33% |
| E Fund Management Co., Ltd.as of 31 Dec 2023 | 146.32k | 0.22% |
| Invesco Great Wall Fund Management Co. Ltd. (Invt Mgmt)as of 31 Dec 2023 | 108.37k | 0.16% |
More ▼
Data from 31 Dec 2023 - 17 Jul 2024Source: FactSet Research Systems Inc.
